I'm LongbridgeAI, I can summarize articles.Regeneron reported Q2 2026 revenue of $4.3 billion and non-GAAP EPS of $14.29. Dupixent global net sales reached $6 billion, up 38% year-over-year. EYLEA HD and U.S. sales totaled $596 million. The company highlighted pipeline progress, including FDA clearance for Otarmeni and expected decisions on cemdisiran.
- Regeneron highlighted Q2 2026 revenue of USD 4.3 billion, non-GAAP EPS of USD 14.29. * Dupixent collaboration showed Q2 global net sales of USD 6 billion, up 38% year over year, with more than 1,500,000 patients on therapy. * Sanofi antibody development balance for Dupixent was fully reimbursed as of June 30, 2026, supporting a step-up in collaboration revenue in Q3. * EYLEA HD and EYLEA U.S. net product sales totaled USD 596 million, with EYLEA HD about 60% of the combined figure. * Pipeline focus included Otarmeni cleared by the FDA for genetic hearing loss, cemdisiran filings in generalized myasthenia gravis with an FDA decision expected in November 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here